These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34188042)

  • 1. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
    Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR
    Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
    Cloughesy TF; Mochizuki AY; Orpilla JR; Hugo W; Lee AH; Davidson TB; Wang AC; Ellingson BM; Rytlewski JA; Sanders CM; Kawaguchi ES; Du L; Li G; Yong WH; Gaffey SC; Cohen AL; Mellinghoff IK; Lee EQ; Reardon DA; O'Brien BJ; Butowski NA; Nghiemphu PL; Clarke JL; Arrillaga-Romany IC; Colman H; Kaley TJ; de Groot JF; Liau LM; Wen PY; Prins RM
    Nat Med; 2019 Mar; 25(3):477-486. PubMed ID: 30742122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways.
    Skadborg SK; Maarup S; Draghi A; Borch A; Hendriksen S; Mundt F; Pedersen V; Mann M; Christensen IJ; Skjøth-Ramussen J; Yde CW; Kristensen BW; Poulsen HS; Hasselbalch B; Svane IM; Lassen U; Hadrup SR
    Cancer Immunol Res; 2024 Sep; 12(9):1202-1220. PubMed ID: 38885356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
    Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
    JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
    Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
    Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
    Lee AH; Sun L; Mochizuki AY; Reynoso JG; Orpilla J; Chow F; Kienzler JC; Everson RG; Nathanson DA; Bensinger SJ; Liau LM; Cloughesy T; Hugo W; Prins RM
    Nat Commun; 2021 Nov; 12(1):6938. PubMed ID: 34836966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
    van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
    Front Immunol; 2021; 12():793964. PubMed ID: 34987518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
    Zhao J; Chen AX; Gartrell RD; Silverman AM; Aparicio L; Chu T; Bordbar D; Shan D; Samanamud J; Mahajan A; Filip I; Orenbuch R; Goetz M; Yamaguchi JT; Cloney M; Horbinski C; Lukas RV; Raizer J; Rae AI; Yuan J; Canoll P; Bruce JN; Saenger YM; Sims P; Iwamoto FM; Sonabend AM; Rabadan R
    Nat Med; 2019 Mar; 25(3):462-469. PubMed ID: 30742119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
    Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
    Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.
    Prakadan SM; Alvarez-Breckenridge CA; Markson SC; Kim AE; Klein RH; Nayyar N; Navia AW; Kuter BM; Kolb KE; Bihun I; Mora JL; Bertalan MS; Shaw B; White M; Kaplan A; Stocking JH; Wadsworth MH; Lee EQ; Chukwueke U; Wang N; Subramanian M; Rotem D; Cahill DP; Adalsteinsson VA; Miller JW; Sullivan RJ; Carter SL; Brastianos PK; Shalek AK
    Nat Commun; 2021 Oct; 12(1):5955. PubMed ID: 34642316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
    Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
    Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
    Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
    J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
    Liu S; Knochelmann HM; Lomeli SH; Hong A; Richardson M; Yang Z; Lim RJ; Wang Y; Dumitras C; Krysan K; Timmers C; Romeo MJ; Krieg C; O'Quinn EC; Horton JD; Dubinett SM; Paulos CM; Neskey DM; Lo RS
    Cell Rep Med; 2021 Oct; 2(10):100411. PubMed ID: 34755131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
    Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P
    Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
    Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
    Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study.
    Restrepo P; Yong R; Laface I; Tsankova N; Nael K; Akturk G; Sebra R; Gnjatic S; Hormigo A; Losic B
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 31907277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.